Natera Partners with Kupando on Phase 1 Trial for Advanced Skin Cancer Immunotherapy — Natera, Inc.

Event summary

Natera’s Latitude tissue-free assay will be used in a Phase 1 trial of Kupando’s immunotherapy candidate KUP-101 for advanced skin cancers.
The trial, sponsored by Kupando Therapeutics, aims to assess circulating tumor DNA (ctDNA) dynamics as part of treatment response monitoring.
First patient dosing has been completed, and the safety committee has approved further enrollment across leading oncology centers in Germany.
KUP-101 is designed to activate the innate immune system and induce trained immunity, with potential as a tissue-agnostic treatment.

The big picture

This collaboration aligns with the growing trend of integrating advanced diagnostics like ctDNA monitoring into immunotherapy trials. Success could position Natera as a key player in molecular response assessment, while Kupando’s KUP-101 represents a novel approach to treating refractory cancers through innate immune activation.

What we're watching

Trial Progress: The pace at which Kupando enrolls patients and generates data on KUP-101’s efficacy will determine the trial’s timeline and potential regulatory path.
Diagnostic Validation: How effectively Natera’s Latitude assay tracks ctDNA dynamics could influence its adoption in other immunotherapy trials.
Commercial Potential: Whether KUP-101’s tissue-agnostic approach succeeds will impact Kupando’s valuation and Natera’s role in precision oncology.